Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Molecular Carcinogenesis

• Publication date

  2003-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/mc.10098PMID 12557260
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comprehensive genome sequence analysis of a breast cancer amplicon.

  2001cited by this paper
• The ZNF217 gene amplified in breast cancers promotes immortalization of human mammary epithelial cells.

  2001cited by this paper
• Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer.

  2001cited by this paper
• B-myb rescues ras-induced premature senescence, which requires its transactivation domain.

  2001cited by this paper
• The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis.

  2001cited by this paper
• Characterization of chromosome aberrations associated with soft‐tissue leiomyosarcomas by twenty‐four‐color karyotyping and comparative genomic hybridization analysis

  2001cited by this paper
• Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma.

  2001cited by this paper
• Centrosomal and cytoplasmic Cdc2/cyclin B1 activation precedes nuclear mitotic events.

  2000cited by this paper
• Ovarian cancer. an institutional review of patterns of care, health insurance and prognosis.

  2000cited by this paper
• Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication.

  2000cited by this paper
• Genetic Aberrations Detected by Comparative Genomic Hybridization in Ovarian Clear Cell Adenocarcinomas

  2000cited by this paper
• Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer.

  2000cited by this paper
• Cancer statistics, 2000

  2000cited by this paper
• The centrosome-associated Aurora/Ipl-like kinase family.

  2000cited by this paper
• An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer.

  2000cited by this paper
• Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data.

  2000cited by this paper
• Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray.

  1999cited by this paper
• Molecular classification of cancer: class discovery and class prediction by gene expression monitoring.

  1999cited by this paper
• Chromosomal gains and losses in primary colorectal carcinomas detected by CGH and their associations with tumour DNA ploidy, genotypes and phenotypes

  1999cited by this paper
• B‐Myb protein in cellular proliferation, transcription control, and cancer: Latest developments

  1999cited by this paper
• Dominant genetic alterations in immortalization: Role for 20q gain

  1999cited by this paper
• Prognostic significance of DNA ploidy and S-phase fraction in malignant serous cystadenocarcinoma of the ovary.

  1998cited by this paper
• Cluster analysis and display of genome-wide expression patterns.

  1998cited by this paper
• CAS, the human homologue of the yeast chromosome-segregation gene CSE1, in proliferation, apoptosis, and cancer.

  1998cited by this paper
• Human Bub1: a putative spindle checkpoint kinase closely linked to cell proliferation.

  1998cited by this paper
• Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation

  1998cited by this paper
• A centrosomal function for the human Nek2 protein kinase, a member of the NIMA family of cell cycle regulators

  1998cited by this paper
• 20q gain associates with immortalization: 20q13.2 amplification correlates with genome instability in human papillomavirus 16 E7 transformed human uroepithelial cells

  1997cited by this paper
• Mammalian BUB1 protein kinases: map positions and in vivo expression.

  1997cited by this paper
• Use of a cDNA microarray to analyse gene expression patterns in human cancer

  1996cited by this paper
• The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma.

  1994cited by this paper
• The role of Myb proteins in normal and neoplastic cell proliferation.

  1994cited by this paper
• Amplified RNA synthesized from limited quantities of heterogeneous cDNA.

  1990cited by this paper
• Cancer statistics

  1989cited by this paper
• Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary.

  1984cited by this paper
• The pathological assessment of ovarian neoplasms. III: The malignant "epithelial" tumours.

  1979cited by this paper
• The origin of malignant tumors

  year unknowncited by this paper

• Letrozole for hormone receptor–positive low-grade ovarian cancer: Preliminary toxicity results of a phase III trial

  2025cites this paper
• Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

  2021cites this paper
• Ubiquitin Proteasome Pathway Transcriptome in Epithelial Ovarian Cancer

  2021cites this paper
• NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021

  2020cites this paper
• Management of Gynecologic Cancers In Relation to Genetic Predisposition.

  2019cites this paper
• Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer

  2019cites this paper
• Proteinexpression von UBE2C, TOP2A, FASN, CCNB1 CDC2 und Ki-67 im Ovarialkarzinom zur Trennung von Low-grade und High-grade

  2019cites this paper
• Genomic heterogeneity in peritoneal implants: A differential analysis of gene expression using nanostring Human Cancer Reference panel identifies a malignant signature.

  2019cites this paper
• Population masculine au sein des familles avec mutation germinale dans les gènes BRCA1 et BRCA2 aspects cliniques et pathologiques des cancers

  2018cites this paper
• B-Myb Mediates Proliferation and Migration of Non-Small-Cell Lung Cancer via Suppressing IGFBP3

  2018cites this paper
• FAST TRACK GENE EXPRESSION PROFILES IN PRIMARY OVARIAN SEROUS PAPILLARY TUMORS AND NORMAL OVARIAN EPITHELIUM: IDENTIFICATION OF CANDIDATE MOLECULAR MARKERS FOR OVARIAN CANCER DIAGNOSIS AND THERAPY

  2018cites this paper
• PERFRINGENS ENTEROTOXIN TO TREAT OVARAN AND UTERINE CANCER

  2017cites this paper
• Hereditary Ovarian Cancer

  2017cites this paper
• Activity of Bevacizumab in Patients With Low-Grade Serous Ovarian Carcinoma

  2016cites this paper
• Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?

  2016cites this paper
• Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015.

  2016cites this paper
• Hereditary breast cancer syndromes and genetic testing

  2015cites this paper
• Genetic/familial high-risk assessment: breast and ovarian, version 1.2014.

  2014cites this paper
• Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version

  2014cites this paper
• Overexpression of WDR62 is associated with centrosome amplification in human ovarian cancer

  2013cites this paper
• Low-grade serous carcinoma: new concepts and emerging therapies.

  2013cites this paper
• Low-grade and high-grade serous Mullerian carcinoma: review and analysis of publicly available gene expression profiles.

  2013cites this paper
• Stage II to IV Low-grade Serous Carcinoma of the Ovary Is Associated With a Poor Prognosis: A Clinicopathologic Study of 32 Patients From a Population-based Tumor Registry

  2013influential citation
• Claudins Overexpression in Ovarian Cancer: Potential Targets for Clostridium Perfringens Enterotoxin (CPE) Based Diagnosis and Therapy

  2013cites this paper
• The life and times of low-grade serous carcinoma of the ovary.

  2013cites this paper
• Survival in Women With Grade 1 Serous Ovarian Carcinoma

  2013cites this paper
• Cellular apoptosis susceptibility (chromosome segregation 1‐like, CSE1L) gene is a key regulator of apoptosis, migration and invasion in colorectal cancer

  2012cites this paper
• Reclassification of serous ovarian carcinoma by a 2‐tier system

  2012cites this paper
• Modelling genetic and clinical heterogeneity in epithelial ovarian cancers.

  2011cites this paper
• Pathogenesis of Ovarian Cancer

  2011cites this paper
• Low-grade serous primary peritoneal carcinoma.

  2010cites this paper
• Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer

  2010cites this paper
• Addiction of MYCN Amplified Tumours to B-MYB Underscores a Reciprocal Regulatory Loop

  2010cites this paper
• Suppression of Aurora-A oncogenic potential by c-Myc downregulation

  2010cites this paper
• Molecular characterization of ovarian cancer by gene-expression profiling.

  2010cites this paper
• Target genes suitable for silencing approaches and protein product interference in ovarian epithelial cancer.

  2010cites this paper
• Genetic/familial high-risk assessment: breast and ovarian.

  2010cites this paper
• BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.

  2010cites this paper
• Subgroups of Ovarian Carinoma: Identification Using Differential Gene Expression

  2010cites this paper
• Translocation t(11;18)(q21;q21) in gastric B‐cell lymphomas

  2009cites this paper
• Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.

  2009cites this paper
• Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.

  2008cites this paper
• New Prognostic Markers in Stage III Serous Ovarian Adenocarcinomas

  2008cites this paper
• Low-grade serous ovarian cancer: a unique disease

  2008cites this paper
• Epidemiology of low-grade serous ovarian cancer.

  2008cites this paper
• Genomic analysis of epithelial ovarian cancer

  2008cites this paper
• Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma.

  2007cites this paper
• Time for action: a "sea change" in treatment strategies for rare types of epithelial ovarian cancer.

  2007cites this paper
• Simultaneous Aurora-A/STK15 overexpression and centrosome amplification induce chromosomal instability in tumour cells with a MIN phenotype

  2007cites this paper
• TITLE : Emerging Roles for PAX 8 in Ovarian Cancer and Endosalpingeal Development

  2007cites this paper
• Molecular Markers in Epithelial Ovarian Cancer

  2007cites this paper
• Amplification and overexpression of Aurora-A in esophageal squamous cell carcinoma.

  2007cites this paper
• Emerging roles for PAX8 in ovarian cancer and endosalpingeal development.

  2007cites this paper
• The continuum of serous tumors of low malignant potential and low-grade serous carcinomas of the ovary.

  2007cites this paper
• Genetic intra‐tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours

  2007cites this paper
• Time for action: A "sea change" in treatment strategies for rare types of epithelial ovarian cancer

  2007cites this paper
• The Continuum of Serous Tumors of Low Malignant Potential and Low-Grade Serous Carcinomas of the Ovary

  2007cites this paper
• Genomic tests for ovarian cancer detection and management.

  2006cites this paper
• Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.

  2006cites this paper
• Clinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the Ovary

  2006cites this paper
• Expression profiling correlates with treatment response in women with advanced serous epithelial ovarian cancer

  2006cites this paper
• Molecular biomarkers: new approaches in ovarian cancer diagnosis

  2006cites this paper
• Molecular prognostic markers in ovarian cancer: toward patient‐tailored therapy

  2006cites this paper
• Systemic therapy for gynecological neoplasms: ovary, cervix, and endometrium.

  2006cites this paper
• Optimisation of cDNA microarray tumour profiling and molecular analysis of epithelial ovarian cancer

  2005cites this paper
• Gene expression profile changes in epithelial ovarian carcinomas using tumor-specific cDNA microarray

  2005cites this paper
• Molecular prognostic markers in ovarian cancer: toward patient-tailored therapy

  2005cites this paper
• Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.

  2005cites this paper
• In silico chromosomal clustering of genes displaying altered expression patterns in ovarian cancer.

  2005influential citation
• Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin.

  2005cites this paper
• Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling.

  2005cites this paper
• Quantitative biochemical analysis of lactate dehydrogenase in human ovarian tissues: correlation with tumor grade

  2005cites this paper
• Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential

  2005cites this paper
• Association of 20q13.2 copy number changes with the advanced stage of ovarian cancer-tissue microarray analysis.

  2005cites this paper
• Centrosome abnormalities in ovarian cancer

  2005cites this paper
• Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin

  2004influential citation
• From Identification of Genomic Polymorphisms to Diagnostic and Prognostic Markers of Human Epithelial Tumors

  2004cites this paper
• Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy

  2004cites this paper
• Biology of epithelial ovarian cancer: implications for screening women at high genetic risk.

  2004cites this paper
• Gene expression profiling of tamoxifen-associated uterine cancers: evidence for two molecular classes of endometrial carcinoma.

  2004cites this paper
• FISH, applications en anatomie pathologique

  2004cites this paper
• Overexpression and Amplification of Aurora-A in Hepatocellular Carcinoma

  2004cites this paper
• Signature of a silent killer: expression profiling in epithelial ovarian cancer

  2004cites this paper
• Subclassification of Ovarian Surface Epithelial Tumors Based on Correlation of Histologic and Molecular Pathologic Data

  2004cites this paper
• Molecular Cancer Gene Expression Profiling of Epithelial Ovarian Tumours Correlated with Malignant Potential

  2004cites this paper
• Genomic and proteomic technologies for individualisation and improvement of cancer treatment.

  2004cites this paper
• Promising directions for the diagnosis and management of gynecological cancers

  2003cites this paper
• Molecular Mechanisms of Pathogenesis and Progression of Epithelial Ovarian Cancer

  2003cites this paper
• Systemic therapy for gynecological neoplasms: ovary, cervix and endometrium.

  2003cites this paper
• Chromosomal changes in ovarian cancer

  2003cites this paper
• Prognostic factors in ovarian cancer: current evidence and future prospects

  2003cites this paper
• Tumor cytosol dipeptidyl peptidase III activity is increased with histological aggressiveness of ovarian primary carcinomas.

  2003cites this paper
• NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ® ) Genetic / Familial High-Risk Assessment : Breast and Ovarian Version 1 . 2018 — October 3

  2001cites this paper